Your search for apixaban returned 4 results

ANNEXA-4 is a global, single-arm, open-label clinical trial designed to evaluate andexanet alfa in patients who present with an acute major bleed while receiving apixaban, rivaroxaban, edoxaban or enoxaparin.

Apixaban is a substrate of P-glycoprotein and P-glycoprotein inhibition increases drug exposure.

End-stage renal disease patients on dialysis with atrial fibrillation are at high risk for thrombotic complications.

Older patients, females, and those with comorbidities were more likely to be on multiple medications.